

# Peter Lindgren

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6338014/publications.pdf>

Version: 2024-02-01

41  
papers

984  
citations

567281

15  
h-index

454955

30  
g-index

43  
all docs

43  
docs citations

43  
times ranked

1619  
citing authors

#	ARTICLE	IF	CITATIONS
1	Cost-effectiveness of proprotein convertase subtilisin/kexin type 9 inhibition with evolocumab in patients with a history of myocardial infarction in Sweden. <i>European Heart Journal Quality of Care &amp; Clinical Outcomes</i> , 2022, 8, 31-38.	4.0	13
2	Something borrowed, something new: measuring hospital performance in the context of value based health care. <i>European Journal of Health Economics</i> , 2021, 22, 851-854.	2.8	0
3	Reduced work absenteeism in patients with hepatitis C treated with second-generation direct-acting antivirals. <i>Journal of Viral Hepatitis</i> , 2021, 28, 142-146.	2.0	3
4	The Key Role of Patient Involvement in the Development of Core Outcome Sets in Prostate Cancer. <i>European Urology Focus</i> , 2021, 7, 943-946.	3.1	6
5	Value appropriation in hepatitis C. <i>European Journal of Health Economics</i> , 2021, , 1.	2.8	2
6	A Swedish primary healthcare prevention programme focusing on promotion of physical activity and a healthy lifestyle reduced cardiovascular events and mortality: 22-year follow-up of 5761 study participants and a reference group. <i>British Journal of Sports Medicine</i> , 2020, 54, 1294-1299.	6.7	11
7	Costs of diabetes complications: hospital-based care and absence from work for 392,200 people with type 2 diabetes and matched control participants in Sweden. <i>Diabetologia</i> , 2020, 63, 2582-2594.	6.3	47
8	Healthcare pathways and resource use: mapping consequences of ambulance assessment for direct care with alternative healthcare providers. <i>BMC Emergency Medicine</i> , 2020, 20, 85.	1.9	0
9	Introducing PIONEER: a project to harness big data in prostate cancer research. <i>Nature Reviews Urology</i> , 2020, 17, 351-362.	3.8	18
10	The cost of cancer in Europe 2018. <i>European Journal of Cancer</i> , 2020, 129, 41-49.	2.8	182
11	Risk sharing in managed entry agreements – A review of the Swedish experience. <i>Health Policy</i> , 2020, 124, 404-410.	3.0	21
12	Days absent from work as a result of complications associated with type 2 diabetes: Evidence from 20 years of linked national registry data in Sweden. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1586-1597.	4.4	15
13	Standardized Questionnaire for the Measurement, Valuation, and Estimation of Costs of Informal Care Based on the Opportunity Cost and Proxy Good Method. <i>Applied Health Economics and Health Policy</i> , 2019, 17, 15-24.	2.1	31
14	Inter-hospital variations in health outcomes in childbirth care in Sweden: a register-based study. <i>International Journal for Quality in Health Care</i> , 2019, 31, 276-282.	1.8	4
15	Exploring staff experience of economic efficiency requirements in health care: A mixed method study. <i>International Journal of Health Planning and Management</i> , 2019, 34, 1439-1455.	1.7	1
16	Incomplete description of the current body of evidence of the health economics of Duchenne muscular dystrophy. <i>Orphanet Journal of Rare Diseases</i> , 2019, 14, 75.	2.7	0
17	&lt;p&gt;Extreme Consumers of Health Care: Patterns of Care Utilization in Patients with Multiple Chronic Conditions Admitted to a Novel Integrated Clinic&lt;/p&gt;. <i>Journal of Multidisciplinary Healthcare</i> , 2019, Volume 12, 1075-1083.	2.7	9
18	Psychometric properties of the Zarit Caregiver Burden Interview administered to caregivers to patients with Duchenne muscular dystrophy: a Rasch analysis. <i>Disability and Rehabilitation</i> , 2019, 41, 966-973.	1.8	10

#	ARTICLE	IF	CITATIONS
19	Psychometric analysis of the pediatric quality of life inventory 3.0 neuromuscular module administered to patients with duchenne muscular dystrophy: A rasch analysis. <i>Muscle and Nerve</i> , 2018, 58, 367-373.	2.2	10
20	Association between sociodemographic determinants and health outcomes in individuals with type 2 diabetes in Sweden. <i>Diabetes/Metabolism Research and Reviews</i> , 2018, 34, e2984.	4.0	9
21	Compliance to care guidelines for Duchenne muscular dystrophy in Italy. <i>Neuromuscular Disorders</i> , 2018, 28, 100.	0.6	2
22	The development and validation of a scale to explore staff experience of governance of economic efficiency and quality (GOV-EQ) of health care. <i>BMC Health Services Research</i> , 2018, 18, 963.	2.2	11
23	Sociodemographic determinants and health outcome variation in individuals with type 1 diabetes mellitus: A register-based study. <i>PLoS ONE</i> , 2018, 13, e0199170.	2.5	15
24	Case mix adjusted variation in cesarean section rate in Sweden. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2017, 96, 597-606.	2.8	19
25	Managerial strategies to make incentives meaningful and motivating. <i>Journal of Health Organization and Management</i> , 2017, 31, 126-141.	1.3	20
26	Professionalsâ€™ perspectives on a market-inspired policy reform: A guiding light to the blind spots of measurement. <i>Health Services Management Research</i> , 2017, 30, 148-155.	1.7	5
27	Cost-effectiveness of Evolocumab in Patients With High Cardiovascular Risk in Spain. <i>Clinical Therapeutics</i> , 2017, 39, 771-786.e3.	2.5	45
28	Cost-effectiveness of Evolocumab Therapy for Reducing Cardiovascular Events in Patients With Atherosclerotic Cardiovascular Disease. <i>JAMA Cardiology</i> , 2017, 2, 1069.	6.1	119
29	Patient Preferences for Treatments of Neuromuscular Diseases: A Systematic Literature Review. <i>Journal of Neuromuscular Diseases</i> , 2017, 4, 285-292.	2.6	4
30	Economic Evaluation in Duchenne Muscular Dystrophy: Model Frameworks for Cost-Effectiveness Analysis. <i>Pharmacoeconomics</i> , 2017, 35, 249-258.	3.3	24
31	Health-related quality of life in patients with Duchenne muscular dystrophy: a multinational, cross-sectional study. <i>Developmental Medicine and Child Neurology</i> , 2016, 58, 508-515.	2.1	82
32	Case mix adjustment of health outcomes, resource use and process indicators in childbirth care: a register-based study. <i>BMC Pregnancy and Childbirth</i> , 2016, 16, 125.	2.4	16
33	Quantifying the burden of caregiving in Duchenne muscular dystrophy. <i>Journal of Neurology</i> , 2016, 263, 906-915.	3.6	82
34	A Cluster-Randomized Controlled Trial Evaluating the Effectiveness and Cost-Effectiveness of Tobacco Cessation on Prescription in Swedish Primary Health Care: A Protocol of the Motivation 2 Quit (M2Q) Study. <i>JMIR Research Protocols</i> , 2016, 5, e188.	1.0	5
35	Compliance to Care Guidelines for Duchenne Muscular Dystrophy. <i>Journal of Neuromuscular Diseases</i> , 2015, 2, 63-72.	2.6	51
36	Time Trends in Incidence and Mortality of Acute Myocardial Infarction, and All-Cause Mortality following a Cardiovascular Prevention Program in Sweden. <i>PLoS ONE</i> , 2015, 10, e0140201.	2.5	17

#	ARTICLE	IF	CITATIONS
37	Determinants of Utility Based on the EuroQol Five-Dimensional Questionnaire in Patients with Chronic Heart Failure and Their Change Over Time: Results from the Swedish Heart Failure Registry. <i>Value in Health</i> , 2015, 18, 439-448.	0.3	23
38	Development and psychometric analysis of the Duchenne muscular dystrophy Functional Ability Self-Assessment Tool (DMDSAT). <i>Neuromuscular Disorders</i> , 2015, 25, 937-944.	0.6	17
39	Abstract 18114: Differences Between Observed and Predicted Cardiovascular Event Rates Using the Framingham and REACH Equations: The Case of High-intensity Statin Users in the United Kingdom. <i>Circulation</i> , 2015, 132, .	1.6	4
40	Health-related quality of life and long-term morbidity and mortality in patients hospitalised with systolic heart failure. <i>JRSM Cardiovascular Disease</i> , 2014, 3, 204800401454873.	0.7	9
41	Costâ€“effectiveness of statins revisited: lessons learned about the value of innovation. <i>European Journal of Health Economics</i> , 2012, 13, 445-450.	2.8	17